Exelixis EXEL
NASDAQ EXEL
$59.02 -0.11 (-0.19%)
As of: Sep 4, 2026 · 3:59 PM EDT

Exelixis (EXEL) Cash from Operations Growth (5y) (2015 - 2026)

Analysis

Exelixis (EXEL) Cash from Operations Growth (5y) (2015 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Exelixis 14.81 Bn 13.97 Bn 608.03 Mn
Historic Data

Historic Data

Download Data
DateValue
Jul 3, 2026 11.14%
Apr 3, 2026 44.81%
Jan 2, 2026 32.51%
Apr 4, 2025 30.40%
Sep 27, 2024 29.12%
Jun 28, 2024 -1.92%
Mar 29, 2024 -15.69%
Dec 29, 2023 -36.77%
Sep 29, 2023 -6.57%
Jun 30, 2023 10.19%
Mar 31, 2023 3.29%
Dec 30, 2022 6.67%
Sep 30, 2022 23.79%
Jul 1, 2022 41.26%
Apr 1, 2022 16.49%
Dec 31, 2021 2.53%
Oct 1, 2021 74.99%
Jul 2, 2021 55.37%
Apr 2, 2021 -24.08%
Apr 3, 2020 26.53%